ALX Oncology Holdings ALXO announced positive interim data from the phase II portion of its phase II/III ASPEN-06 study evaluating its lead candidate evorpacept as part of a four-drug combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results